ERBB2 and breast cancer: In HER2-positive and triple-negative (TN) BC patients treated with neoadjuvant chemotherapy (NACT), higher stromal tumour-infiltrating lymphocytes (sTILs) have been associated with a better prognosis [2,3] and a higher probability of achieving pathological complete response (pCR) [4].